Ikena Oncology, Inc. (IKNA)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about Ikena Oncology, Inc. (IKNA)
Company Performance

Current Price

as of Oct 18, 2024

$1.71

P/E Ratio

N/A

Market Cap

$82.52M

Description

Ikena Oncology, Inc. is a clinical stage biotechnology company, which engages in the development of patient directed and biomarker driven therapies for cancer patients. Its product pipeline includes IK-930, RAS Signaling, IK-175, IK-412, and IK-007. The company was founded by Mark Manfredi and George Georgiou in February 2016 and is headquartered in Boston, MA.

Metrics

Overview

  • HQBoston, MA
  • SectorHealth Technology
  • IndustryBiotechnology
  • TickerIKNA
  • Price$1.710.00%

Trading Information

  • Market Cap$82.52M
  • Float61.08%
  • Average Daily Volume (1m)37,054
  • Average Daily Volume (3m)57,247
  • EPS-$1.43

Company

  • Revenue$1.84M
  • Rev Growth (1yr)-100.00%
  • Net Income-$13.73M
  • Gross MarginN/A
  • EBITDA MarginN/A
  • EBITDA-$15.05M
  • EV-$56.70M
  • EV/Revenue-30.75
  • P/EN/A
  • P/S44.75
  • P/B0.58
Documents